This clinical trial is focused on studying a condition known as chronic rhinosinusitis with nasal polyps. This is a long-term inflammation of the sinuses that leads to the growth of polyps, which are small, non-cancerous swellings inside the nose. The trial will test a treatment called itepekimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body. In this case, itepekimab targets a protein called interleukin-33, which is involved in the inflammation process. The study will compare the effects of itepekimab to a placebo, which is a substance with no active medication, to see how well it works in reducing the size of nasal polyps and relieving nasal congestion.

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of itepekimab in adults who have chronic rhinosinusitis with nasal polyps that are not well controlled. Participants in the study will receive either itepekimab or a placebo through an injection once a week for a total of 52 weeks, which is about one year. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if itepekimab can help reduce the symptoms of nasal polyps and improve the quality of life for those affected by this condition.

By participating in this study, researchers hope to gather important information about how itepekimab can help people with chronic rhinosinusitis with nasal polyps. This could lead to better treatment options in the future for those suffering from this condition. The study will also monitor any side effects or adverse reactions to ensure the safety of the participants. The results of this study could provide valuable insights into managing and treating chronic rhinosinusitis with nasal polyps more effectively.